The value and effectiveness of angiogenesis inhibitors for colorectal cancer.

Subjects

Subjects :

Angiogenesis Inhibitors pharmacology
Antibodies, Monoclonal pharmacology
Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents pharmacology
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bevacizumab pharmacology
Bevacizumab therapeutic use
Clinical Trials as Topic
Colorectal Neoplasms pathology
Drug Approval
Humans
Neovascularization, Pathologic drug therapy
Phenylurea Compounds pharmacology
Phenylurea Compounds therapeutic use
Pyridines pharmacology
Pyridines therapeutic use
Receptors, Vascular Endothelial Growth Factor pharmacology
Receptors, Vascular Endothelial Growth Factor therapeutic use
Recombinant Fusion Proteins pharmacology
Recombinant Fusion Proteins therapeutic use
Treatment Outcome
United States
United States Food and Drug Administration
Ramucirumab
Angiogenesis Inhibitors therapeutic use
Antineoplastic Agents therapeutic use
Colorectal Neoplasms drug therapy

Details

Language :

English

ISSN :

1543-0790

Volume :

13

Issue :

9

Database :

MEDLINE

Journal :

Clinical advances in hematology & oncology : H&O

Accession number :

26452184